Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

AIM: We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide 2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL). MATERIALS AND METHODS: AE analyses pooled data from the Semaglutide Treatment Effect in People With Obesity (STEP) 1‐3 tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wharton, Sean, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Goldman, Bryan, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Thomsen, Mette, Wadden, Thomas A., Pedersen, Sue D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293236/
https://www.ncbi.nlm.nih.gov/pubmed/34514682
http://dx.doi.org/10.1111/dom.14551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293236/
https://www.ncbi.nlm.nih.gov/pubmed/34514682
http://dx.doi.org/10.1111/dom.14551

Ejemplares similares